Latanoprost Macarthys Laboratories (Latanoprost)

Latanoprost mimics prostaglandin F2α and binds to FP receptors in the ciliary body. This triggers remodeling of extracellular matrix proteins, which increases uveoscleral outflow of aqueous humor. The enhanced outflow reduces intra‑ocular pressure, addressing the primary cause of glaucoma progression.

The prescribed dose of latanoprost is determined by the treating ophthalmologist based on the patient’s intra‑ocular pressure, severity of disease, and response to therapy. Typically, one drop is instilled in the affected eye(s) once daily, but the exact regimen is individualized by the prescriber.

Safety data for latanoprost in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then provides pricing, availability, shipping details and any required import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blockers or carbonic anhydrase inhibitors, prostaglandin analogues often achieve greater pressure lowering with a favorable dosing schedule, though individual response and side‑effect profiles vary.

Latanoprost ophthalmic solution should be stored at ambient temperature, protected from light and freezing. Keep the bottle tightly closed in its original packaging, and avoid exposing it to excessive heat or moisture. Discard any solution that appears discolored or contains particles.

Latanoprost is administered as a single drop placed in the conjunctival sac of the affected eye(s) once daily, usually in the evening. Patients should wash their hands, avoid touching the tip of the bottle, and wait a few minutes before applying other eye drops to ensure proper absorption.

Serious risks, though rare, include inflammatory eye conditions such as uveitis or iritis, corneal edema, and sudden loss of visual acuity. Patients should report any severe eye pain, redness, vision changes, or allergic reactions promptly to their eye care professional.

Latanoprost should not be used by individuals with known hypersensitivity to latanoprost or any excipients in the formulation. Caution is advised for patients with active ocular infections, severe inflammation, or a history of adverse reactions to prostaglandin analogues. The prescriber will assess suitability before initiating therapy.